On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
-
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
-
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
-
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
-
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
-
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
-
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
-
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
-
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
-
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
-
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
-
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
-
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
-
BUSINESS Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
-
ORGANIZATION No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
-
BUSINESS Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
-
ORGANIZATION JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
-
REGULATORY Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
-
REGULATORY CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
-
BUSINESS Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…